A group of medicines approved to treat type 2 diabetes and obesity, which include semaglutide, have passed a safety review by the European Medicines Agency. The review was triggered by reports linking use of the drugs, which are glucagon-like peptide-1 receptor agonists (GLP-1), to suicidal and self-harm thoughts and behaviour. On 12 April, the agency’s pharmacovigilance risk assessment committee (PRAC) said an investigation could not establish a causal association between the medicines and the health risks.
